Document:

Exhibit 10.1

 

NOTE
PURCHASE AGREEMENT

 

THIS
NOTE PURCHASE AGREEMENT (“Agreement”) is made as of November 23, 2019 by and among Mateon Therapeutics,
Inc., a Delaware corporation (the “Company”), and the lenders (each individually a “Lender,”
and collectively the “Lenders”) named on the Schedule of Lenders attached hereto (the “Schedule of Lenders”).
Capitalized terms used but not defined herein shall have the respective meanings ascribed to such terms in the Notes (as defined
below).

 

WHEREAS,
the Lenders wish to provide financing to the Company through the issuance by the Company to the Lenders of Notes (as defined below)
in the aggregate principal amount of up to $1,500,000 during the period beginning on November 23, 2019 and ending on December
7, 2019, and the Company desires to accept such financing pursuant to the terms and conditions set forth below, with the conversion
price of the Notes to be issued at each Closing to be determined by the Company (and agreed to by the Lenders) from time to time
based on the trading price of the Common Stock;

 

NOW
THEREFORE, in consideration of the mutual promises and covenants set forth herein, and for other good and valuable consideration,
the receipt and sufficiency of which is hereby acknowledged, the Company and the Lenders agree as follows:

 

1.
Definitions.

 

(a)
“Change of Control” shall mean:

 

(i)
The acquisition by any individual, entity or group (within the meaning of Rule 13d-3 promulgated under the Securities Exchange
Act of 1934, as amended (the “Exchange Act”) or any successor provision) (any of the foregoing hereafter a
“Person”) of forty percent (40%) or more of either (a) the then outstanding shares of the capital stock of
the Company (the “Outstanding Capital Stock”) or (b) the combined voting power of the then outstanding voting
securities of the Company entitled to vote generally in the election of directors (the “Voting Securities”),
provided, however, that such an acquisition by one of the following shall not constitute a change of control: (1)
the Company or any of its subsidiaries, or any employee benefit plan (or related trust) sponsored or maintained by the Company
or any of its subsidiaries or (2) any Person that is eligible, pursuant to Rule 13d-1(b) under the Exchange Act, to file a statement
on Schedule 13G with respect to its beneficial ownership of Voting Securities, whether or not such Person shall have filed a statement
on Schedule 13G, unless such Person shall have filed a statement on Schedule 13D with respect to beneficial ownership of fifty
percent (50%) or more of the Voting Securities or (3) any corporation with respect to which, following such acquisition, more
than sixty percent (60%) of both the then outstanding shares of common stock of such corporation and the combined voting power
of the then outstanding voting securities of such corporation entitled to vote generally in the election of directors is then
beneficially owned, directly or indirectly, by all or substantially all of the individuals and entities who were the beneficial
owners, respectively, of the Outstanding Capital Stock or Voting Securities immediately prior to such acquisition in substantially
the same proportions as their ownership, immediately prior to such acquisition, of the Outstanding Capital Stock or Voting Securities,
as the case may be; or

 

    	 

    	 

    

 

(ii)
Approval by the shareholders of the Company of a reorganization, merger or consolidation (a “Business Combination”),
in each case, with respect to which all or substantially all holders of the Outstanding Capital Stock and Voting Securities immediately
prior to such Business Combination do not, following such Business Combination, beneficially own, directly or indirectly, in substantially
the same proportions, more than sixty percent (60%) of, respectively, the then outstanding shares of common stock and the combined
voting power of the then outstanding voting securities entitled to vote generally in the election of directors, as the case may
be, of the corporation resulting from the Business Combination; or

 

(iii)
A sale or other disposition of all or substantially all of the assets of the Company other than to a corporation with respect
to which, following such sale or disposition, more than sixty percent (60%) of the then outstanding shares of common stock and
the combined voting power of the then outstanding voting securities entitled to vote generally in the election of directors are
then owned beneficially, directly or indirectly, by all or substantially all of the individuals and entities who were the beneficial
owners, respectively, of the Outstanding Capital Stock or Voting Securities immediately prior to such sale or disposition in substantially
the same proportions as their ownership of the Outstanding Capital Stock and Voting Securities, as the case may be, immediately
prior to such sale or disposition.

 

(b)
“Common Stock” shall mean the shares of the common stock, par value $0.01 per share, of the Company.

 

(c)
“Consideration” shall mean the amount of money paid by each Lender pursuant to this Agreement as shown on the
Schedule of Lenders.

 

(d)
“Majority Note Holders” shall mean the holders of a majority in interest of the aggregate principal amount
of Notes that are outstanding at the time of such calculation.

 

(e)
“Maturity Date” shall be as set forth in each Note (as defined below).

 

(f)
“Notes” shall mean the one or more promissory notes issued to each Lender pursuant to Section 2.1 below, the
form of which is attached hereto as Exhibit A.

 

2.
Amount and Terms of the Notes.

 

2.1
Issuance of Notes. In return for the Consideration paid by the Lender, the Company shall sell and issue to such Lender
one or more Notes. Each Note shall have a principal balance equal to that portion of the Consideration paid by such Lender for
the Note, as set forth in the Schedule of Lenders. Each Note shall be convertible as set forth in the Notes.

 

    	2

    	 

    

 

3.
Closing Mechanics.

 

3.1
Closing. The initial closing (the “Initial Closing”) of the purchase of the Notes in return for the
Consideration paid by each Lender shall take place at such other time and place as the Company and the Lenders purchasing a majority
of the Notes to be sold at the Initial Closing (based upon aggregate principal amount) agree upon orally or in writing. At the
Initial Closing, each Lender shall deliver the Consideration to the Company, and the Company shall deliver to each Lender one
or more executed Notes, in return for the respective Consideration provided to the Company.

 

3.2
Subsequent Closings. In any subsequent closing (each a “Subsequent Closing”, and together with the Initial
Closing, the “Closings”), the Company may sell additional Notes subject to the terms of this Agreement to any
Lender as it shall select. Any subsequent purchasers of Notes shall become a party to, and shall be entitled to receive Notes
in accordance with, this Agreement by submitting to the Company a fully executed Counterpart Signature Page to Note Purchase Agreement,
in the form attached hereto as Exhibit B. Each Subsequent Closing shall take place at such locations and at such times
as shall be mutually agreed upon orally or in writing by the Company and such purchasers of additional Notes. Any Notes sold pursuant
to this Section 3.2 shall be deemed to be “Notes” for all purposes under this Agreement and any purchasers thereof
shall be deemed to be “Lenders” under this Agreement. The Schedule of Lenders to this Agreement shall be updated to
reflect the principal amount of each Note purchased at each Subsequent Closing and the parties purchasing such Notes.

 

4.
Representations and Warranties of the Company. In connection with the purchase and sale of Notes provided for herein, the
Company hereby represents and warrants to the Lenders as of the date hereof that:

 

4.1
Organization, Good Standing and Qualification. The Company is a corporation validly existing and in good standing under
the laws of the State of Delaware and has all requisite power and authority to carry on its business as now conducted. The Company
is duly qualified to transact business and is in good standing in each jurisdiction in which the failure to so qualify would have
a material adverse effect on its business or properties.

 

4.2
Authorization. All Company action has been taken on the part of the Company necessary for the authorization, execution
and delivery of this Agreement and the Notes. Except as may be limited by applicable bankruptcy, insolvency, reorganization or
similar laws relating to or affecting the enforcement of creditors’ rights, the Company has taken all action required to
make all of the obligations of the Company reflected in the provisions of this Agreement and the Notes, the valid and enforceable
obligations they purport to be.

 

4.3
Compliance with Other Instruments. Neither the authorization, execution and delivery of this Agreement, nor the issuance
and delivery of the Notes, will constitute or result in a material default or violation of any law or regulation applicable to
the Company or any material term or provision of the Company’s current Certificate of Incorporation, By-laws or any material
agreement or instrument by which it is bound or to which its properties or assets are subject.

 

    	3

    	 

    

 

5.
Representations and Warranties of the Lenders. In connection with the purchase and sale of Notes provided for herein, each
Lender hereby represents and warrants to the Company that:

 

5.1
Authorization. This Agreement constitutes such Lender’s valid and legally binding obligation, enforceable in accordance
with its terms, except as may be limited by (i) applicable bankruptcy, insolvency, reorganization or similar laws relating to
or affecting the enforcement of creditors’ rights and (ii) laws relating to the availability of specific performance, injunctive
relief or other equitable remedies. Each Lender represents that it has full power and authority to enter into this Agreement.

 

5.2
Purchase Entirely for Own Account. Each Lender acknowledges that this Agreement is made with Lender in reliance upon such
Lender’s representation to the Company that the Notes and the shares of Common Stock issuable upon conversion of the Notes
(collectively, the “Securities”) will be acquired for investment for Lender’s own account, not as a nominee
or agent, and not with a view to the resale or distribution of any part thereof, and that such Lender has no present intention
of selling, granting any participation in, or otherwise distributing the same. By executing this Agreement, each Lender further
represents that such Lender does not have any contract, undertaking, agreement or arrangement with any person to sell, transfer
or grant participations to such person or to any third person, with respect to the Securities.

 

5.3
Disclosure of Information. Each Lender acknowledges that it has received all the information it considers necessary or
appropriate for deciding whether to acquire the Securities. Each Lender further represents that it has had an opportunity to ask
questions of and receive answers from the Company regarding the terms and conditions of the offering of the Securities, and that
such questions have been answered to such Lender’s satisfaction.

 

5.4
Investment Experience. Each Lender is an investor in securities of companies in the development stage and acknowledges
that it is able to fend for itself, can bear the economic risk of its investment and has such knowledge and experience in financial
or business matters that it is capable of evaluating the merits and risks of the investment in the Securities. If other than an
individual, each Lender also represents it has not been organized solely for the purpose of acquiring the Securities.

 

5.5
Accredited Investor. Each Lender is an “accredited investor” within the meaning of Rule 501 of Regulation D
of the Securities Act of 1933 as amended (the “Securities Act”), as presently in effect, and has checked the
applicable box on Exhibit C attached to this Agreement as to the Lender’s qualification as an accredited investor.

 

5.6
Restricted Securities. Each Lender understands that the Securities are characterized as “restricted securities”
under the federal securities laws inasmuch as they are being acquired from the Company in a transaction not involving a public
offering and that under such laws and applicable regulations such securities may be resold without registration under the Securities
Act only in certain limited circumstances. Each Lender represents that it is familiar with Rule 144 promulgated under the Securities
Act, as presently in effect, and understands the resale limitations imposed thereby and by the Securities Act.

 

    	4

    	 

    

 

5.7
Further Limitations on Disposition. Without in any way limiting the representations and warranties set forth above, each
Lender further agrees not to make any disposition of all or any portion of the Securities unless and until the transferee has
agreed in writing for the benefit of the Company to be bound by this Section 5 and Section 7.11, and:

 

(a)
There is then in effect a registration statement under the Securities Act covering such proposed disposition and such disposition
is made in accordance with such registration statement; or

 

(b)
(i) Lender has notified the Company of the proposed disposition and has furnished the Company with a detailed statement of the
circumstances surrounding the proposed disposition and (ii) if reasonably requested by the Company, Lender shall have furnished
the Company with an opinion of counsel, reasonably satisfactory to the Company, that such disposition will not require registration
of such shares under the Securities Act.

 

5.8
Legends. It is understood that the Securities may bear a legend substantially as follows:

 

“THESE
SECURITIES HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED. THEY MAY NOT BE SOLD, OFFERED FOR SALE, PLEDGED,
HYPOTHECATED OR OTHERWISE TRANSFERRED EXCEPT PURSUANT TO AN EFFECTIVE REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933,
AS AMENDED, OR AN OPINION OF COUNSEL SATISFACTORY TO THE COMPANY THAT REGISTRATION IS NOT REQUIRED UNDER SUCH ACT OR UNLESS SOLD
PURSUANT TO RULE 144 UNDER SUCH ACT.”

 

6.
Defaults and Remedies.

 

6.1
Events of Default. The following events shall be considered Events of Default with respect to each Note:

 

(a)
The Company shall default in the payment of any part of the principal or unpaid accrued interest on the Note for more than thirty
(30) days after the Maturity Date or at a date fixed by acceleration or otherwise;

 

(b)
The Company shall make an assignment for the benefit of creditors, or shall admit in writing its inability to pay its debts as
they become due, or shall file a voluntary petition for bankruptcy, or shall file any petition or answer seeking for itself any
reorganization, arrangement, composition, readjustment, dissolution or similar relief under any present or future statute, law
or regulation, or shall file any answer admitting the material allegations of a petition filed against the Company in any such
proceeding, or shall seek or consent to or acquiesce in the appointment of any trustee, receiver or liquidator of the Company,
or of all or any substantial part of the properties of the Company, or the Company or its directors shall take any action looking
to the dissolution or liquidation of the Company;

 

    	5

    	 

    

 

(c)
Within thirty (30) days after the commencement of any proceeding against the Company seeking any bankruptcy reorganization, arrangement,
composition, readjustment, liquidation, dissolution or similar relief under any present or future statute, law or regulation,
such proceeding shall not have been dismissed, or within thirty (30) days after the appointment without the consent or acquiescence
of the Company of any trustee, receiver or liquidator of the Company or of all or any substantial part of the properties of the
Company, such appointment shall not have been vacated;

 

(d)
The Company shall fail to observe or perform any other obligation to be observed or performed by it under this Agreement or the
Notes within thirty (30) days after written notice from the Majority Note Holders to perform or observe such obligation; or

 

(e)
A Change of Control Event with respect to the Company shall have occurred.

 

6.2
Remedies. Upon the occurrence of an Event of Default under Section 6.1 hereof, at the option and upon the declaration of
the Majority Note Holders, the entire unpaid principal and accrued and unpaid interest on the Notes shall, without presentment,
demand, protest, or notice of any kind, all of which are hereby expressly waived, be forthwith due and payable, and the holders
of the Notes may, immediately and without expiration of any period of grace, enforce payment of all amounts due and owing under
the Notes and exercise any and all other remedies granted at law, in equity or otherwise.

 

7.
Miscellaneous.

 

7.1
Successors and Assigns. Except as otherwise provided herein, the terms and conditions of this Agreement shall inure to
the benefit of and be binding upon the respective successors and assigns of the parties. Nothing in this Agreement, express or
implied, is intended to confer upon any party other than the parties hereto or their respective successors and assigns any rights,
remedies, obligations or liabilities under or by reason of this Agreement, except as expressly provided in this Agreement.

 

7.2
Governing Law. This Agreement and the Notes shall be governed by and construed under the laws of the State of New York
as applied to agreements among New York residents, made and to be performed entirely within the State of New York. Each Lender
hereby expressly consents to the exclusive jurisdiction of the state and federal courts situated in the City, County and State
of New York for all actions arising out of, or relating to this Agreement, and irrevocably waives the defense of inconvenient
forum to the maintenance of such action or proceeding.

 

7.3
Execution. This Agreement may be executed in two or more counterparts, each of which shall be deemed an original, but all
of which together shall constitute one and the same instrument. In the event that any signature is delivered by facsimile transmission
or by e-mail delivery of a “.pdf” format data file, such signature shall create a valid and binding obligation of
the party execution (or on whose behalf such signature is executed) with the same force and effect as if such facsimile or “.pdf”
signature page were an original thereof.

 

    	6

    	 

    

 

7.4
Titles and Subtitles. The titles and subtitles used in this Agreement are used for convenience only and are not to be considered
in construing or interpreting this Agreement.

 

7.5 Notices.
All notices and other communications given or made pursuant hereto shall be in writing and shall be deemed effectively given:
(i) upon personal delivery to the party to be notified; (ii) when sent by confirmed electronic mail or facsimile if sent
during normal business hours of the recipient, if not so confirmed, then on the next business day; (iii) five (5) days after
having been sent by registered or certified mail, return receipt requested, postage prepaid; or (iv) one (1) day after
deposit with a nationally recognized overnight courier, specifying next day delivery, with written verification of receipt.
All communications shall be sent to the respective parties at the following addresses (or at such other addresses as shall be
specified by notice given in accordance with this Section 7.5):

 

If
to the Company:

 

Mateon
Therapeutics Inc.

29397
Agoura Road, Suite 107

Agoura
Hills, CA 91301

Attn:
Chief Executive Officer

 

If
to Lenders:

 

At
the respective addresses shown on the signature pages hereto.

 

7.6
Finder’s Fee. Each party represents that it neither is nor will be obligated for any finder’s fee or commission
in connection with this transaction. Lender agrees to indemnify and to hold harmless the Company from any liability for any commission
or compensation in the nature of a finder’s fee (and the costs and expenses of defending against such liability or asserted
liability) for which Lender or any of its officers, partners, employees or representatives is responsible. The Company agrees
to indemnify and hold harmless Lender from any liability for any commission or compensation in the nature of a finder’s
fee (and the costs and expenses of defending against such liability or asserted liability) for which the Company or any of its
officers, employees or representatives is responsible.

 

7.7
Expenses. If any action at law or in equity is necessary to enforce or interpret the terms of this Agreement, the prevailing
party shall be entitled to reasonable attorneys’ fees, costs and necessary disbursements in addition to any other relief
to which such party may be entitled. Each party hereto shall pay all costs and expenses that it incurs with respect to the negotiation,
execution, delivery and performance of this Agreement.

 

    	7

    	 

    

 

7.8
Entire Agreement; Amendments and Waivers. This Agreement and the Notes and the other documents delivered pursuant hereto
constitute the full and entire understanding and agreement between the parties with regard to the subjects hereof and thereof.
The Company’s agreements with each of the Lenders are separate agreements, and the sales of the Notes to each of the Lenders
are separate sales. Nonetheless, any term of this Agreement or the Notes may be amended and the observance of any term of this
Agreement or the Notes may be waived (either generally or in a particular instance and either retroactively or prospectively),
with the written consent of the Company and the Majority Note Holders. Any waiver or amendment effected in accordance with this
Section shall be binding upon each party to this Agreement and any holder of any Note purchased under this Agreement at the time
outstanding and each future holder of all such Notes.

 

7.9
Effect of Amendment or Waiver. Each Lender acknowledges that by the operation of Section 7.8 hereof, the Majority Note
Holders will have the right and power to diminish or eliminate all rights of such Lender under this Agreement and each Note issued
to such Lender.

 

7.10
Severability. If one or more provisions of this Agreement are held to be unenforceable under applicable law, such provision
shall be excluded from this Agreement and the balance of this Agreement shall be interpreted as if such provision were so excluded
and shall be enforceable in accordance with its terms.

 

7.11
Exculpation Among Lenders. Each Lender acknowledges that it is not relying upon any person, firm, corporation or stockholder,
other than the Company and its officers and directors in their capacities as such, in making its investment or decision to invest
in the Company. Each Lender agrees that no other Lender nor the respective controlling persons, officers, directors, partners,
agents, stockholders or employees of any other Lender shall be liable for any action heretofore or hereafter taken or omitted
to be taken by any of them in connection with the purchase and sale of the Securities.

 

7.12
Acknowledgement. In order to avoid doubt, it is acknowledged that each Lender shall be entitled to the benefit of all adjustments
in the number of shares of Common Stock of the Company issuable as a result of any splits, recapitalizations, combinations or
other similar transaction affecting the Common Stock that occur prior to the conversion of the Notes.

 

7.13
Indemnity; Costs, Expenses and Attorneys’ Fees. The Company shall indemnify and hold each Lender harmless from any
loss, cost, liability and legal or other expense, including attorneys’ fees of such Lender’s counsel, which a Lender
may directly or indirectly suffer or incur by reason of the failure of the Company to perform any of its obligations under this
Agreement, any Note, any agreement executed in connection herewith or therewith, any grant of or exercise of remedies with respect
to any collateral at any time securing any obligations evidenced by this Agreement or the Notes, or any Lender’s execution
or performance of this Agreement or any agreement executed in connection herewith, provided, however, that the indemnity agreement
contained in this section shall not apply to liabilities that a Lender may directly or indirectly suffer or incur by reason of
such Lender’s own gross negligence, willful misconduct or fraud.

 

7.14
Further Assurance. From time to time, the Company shall execute and deliver to the Lenders such additional documents and
shall provide such additional information to the Lenders as the Majority Note Holders may reasonably require to carry out the
terms of this Agreement and the Notes, and any agreements executed in connection herewith or therewith.

 

7.15.
Confidentiality. Each Lender acknowledges and agrees that any information or data it has acquired from or about the Company,
not otherwise properly in the public domain, was received in confidence. Each Lender agrees not to divulge, communicate or disclose,
except as may be required by law or for the performance of this Agreement, or use to the detriment of the Company or for the benefit
of any other person or persons, or misuse in any way, any confidential information of the Company, including any technical, trade
or business secrets of the Company and any technical, trade or business materials that are treated by the Company as confidential
or proprietary, and confidential information obtained by or given to the Company about or belonging to third parties.

 

[remainder
of page intentionally left blank; signature page follows]

 

    	8

    	 

    

 

IN
WITNESS WHEREOF, the parties have executed this Agreement as of the date first written above.

 

	 	Mateon
    Therapeutics, Inc.
	 	 	 
	 	By:
    	            
	 	Name:	 
	 	Title:	 

 

    	 

    	 

    

 

IN
WITNESS WHEREOF, the parties have executed this Agreement as of the date first written above.

 

	 	LENDER:
	 	 	 
	 	By:	              
	 	Name:
    	 
	 	Title:
    	 

 

	 	Address:	 

 

    	 

    	 

    

 

SCHEDULE
OF LENDERS

 

	Lender	 	Note
    Amount
	 	 	 
	[___]	 	[$_______]

 

    	 

    	 

    

 

EXHIBIT
A

 

Form
of Convertible Promissory Note

 

    	 

    	 

    

 

EXHIBIT
B

 

MATEON
THERAPEUTICS, INC.

COUNTERPART
SIGNATURE PAGE TO

NOTE
PURCHASE AGREEMENT

 

Pursuant
to Section 3.2 of that certain Note Purchase Agreement, dated as of November 23rd, 2019, by and among Mateon Therapeutics,
Inc., a Delaware corporation (the “Company”), and the lenders named on the Schedule of Lenders attached thereto
(as may be amended from time to time, the “Purchase Agreement”), and in consideration of the issuance by the
Company of a Note with a principal amount of $________________ in exchange for the Consideration of $_________________ paid by
the undersigned, the undersigned hereby agrees to be bound by and to observe all of the terms and conditions of the Purchase Agreement
and all of the benefits of the Purchase Agreement shall inure to the undersigned as a Lender thereunder. The undersigned hereby
represents and warrants that all of the representations contained in Section 5 of the Purchase Agreement are true and correct
as of the date hereof. The undersigned hereby authorizes the Company to attach this counterpart signature page to the Purchase
Agreement. Capitalized terms used but not defined herein shall have the meanings ascribed thereto in the Purchase Agreement or
in the Note, as applicable.

 

Dated
as of November 23, 2019

 

	 	LENDER:
	 	 	 
	 	Name:	 
	 	Address:	 
	 	 	 

 

	 	Principal
    Amount of Note: 	 

 

    	 

    	 

    

 

EXHIBIT
C

 

ACCREDITED
INVESTOR QUESTIONNAIRE

 

	A.	APPLICABLE
    TO INDIVIDUALS ONLY. Please answer the following questions concerning your financial condition as an “accredited
    investor” (within the meaning of Rule 501 of Regulation D). If the Purchaser is more than one individual, each individual
    must initial an answer where the question indicates a “yes” or “no” response, indicating to which
    individual it applies. The Purchaser must answer “yes” in response to question 1, 2 or 3 below to be considered
    an “accredited investor.” If the Purchaser is purchasing jointly with his or her spouse, one answer may be indicated
    for the couple as a whole:

 

	 	1.	Does
    your net worth*, or joint net worth with your spouse, exceed $1,000,000?

 

	Yes______	 	No______

 

	 	2.	Did
    you have an individual income ** in excess of $200,000, or joint income together with your spouse in excess of $300,000, in
    each of the two most recent years and do you reasonably expect to reach the same income level in the current year?

 

	Yes______	 	No______

 

	 	3.	Are
    you an executive officer or director of the issuer?

 

	Yes______	 	No______

 

	*	For
    purposes hereof net worth shall be deemed to include ALL of your assets, liquid or illiquid (including such items as furnishings,
    automobile and restricted securities), exclusive of the value of your principal residence, MINUS any liabilities (including
    such items as home mortgages and other debts and liabilities).
	 	 
	**	For
    purposes hereof the term “income” is not limited to “adjusted gross income” as that term is defined
    for federal income tax purposes, but rather includes certain items of income which are deducted in computing “adjusted
    gross income.” For investors who are salaried employees, the gross salary of such investor, minus any significant expenses
    personally incurred by such investor in connection with earning the salary, plus any income from any other source including
    unearned income, is a fair measure of “income” for purposes hereof. For investors who are self-employed, “income”
    is generally construed to mean total revenues received during the calendar year minus significant expenses incurred in connection
    with earning such revenues.

 

    	 

    	 

    

 

	B.	APPLICABLE
    TO CORPORATIONS, PARTNERSHIPS AND OTHER ENTITIES ONLY:

 

The
Purchaser is an accredited investor because the Purchaser falls within at least one of the following categories (Check all appropriate
lines):

 

	 	______	(i)
    a bank as defined in Section 3(a)(2) of the Securities Act or a savings and loan association or other institution as defined
    in Section 3(a)(5)(A) of the Securities Act whether acting in its individual or fiduciary capacity;
	 	 	 
	 	______	(ii)
    a broker-dealer registered pursuant to Section 15 of the Securities Exchange Act of 1934, as amended;
	 	 	 
	 	______	(iii)
    an insurance company as defined in Section 2(13) of the Securities Act;
	 	 	 
	 	______	(iv)
    an investment company registered under the Investment Company Act of 1940, as amended (the “Investment Company Act”)
    or a business development company as defined in Section 29(a)(48) of the Investment Company Act;
	 	 	 
	 	______	(v)
    a Small Business Investment Company licensed by the U.S. Small Business Administration under Section 301(c) or (d) of the
    Small Business Investment Act of 1958, as amended;
	 	 	 
	 	______	(vi)
    a plan established and maintained by a state, its political subdivisions, or any agency or instrumentality of a state or its
    political subdivisions, for the benefit of its employees, where such plan has total assets in excess of $5,000,000;
	 	 	 
	 	______	(vii)
    an employee benefit plan within the meaning of Title 1 of the Employee Retirement Income Security Act of 1974, as amended
    (“ERISA”), where the investment decision is made by a plan fiduciary, as defined in Section 3(21) of ERISA, which
    is either a bank, savings and loan association, insurance company, or registered investment adviser, or an employee benefit
    plan that has total assets in excess of $5,000,000, or a self-directed plan the investment decisions of which are made solely
    by persons that are accredited investors;
	 	 	 
	 	______	(viii)
    a private business development company, as defined in Section 202(a)(22) of the Investment Advisers Act of 1940, as amended;
	 	 	 
	 	______	(ix)
    an organization described in Section 501(c)(3) of the Internal Revenue Code, a corporation, a Massachusetts or similar business
    trust, or a partnership, not formed for the specific purpose of acquiring the securities offered, with total assets in excess
    of $5,000,000;
	 	 	 
	 	______	(x)
    a trust, with total assets in excess of $5,000,000, not formed for the specific purpose of acquiring the securities offered,
    whose purchase is directed by a “sophisticated” person, who has such knowledge and experience in financial and
    business matters that he is capable of evaluating the merits and risks of the prospective investment;
	 	 	 
	 	______	(xi)
    an entity in which all of the equity investors are persons or entities described above (“accredited investors”).
    ALL EQUITY OWNERS MUST COMPLETE PART “A” ABOVE.EXHIBIT 10.1

EXECUTIVE EMPLOYMENT AGREEMENT 

THIS EXECUTIVE EMPLOYMENT
AGREEMENT (this “Agreement”), effective as of October 15, 2019, (the “Effective Date”) is made and entered
by and between CareClix, Inc., a Virginia corporation (the “Company”), Solei Systems, Inc., a Florida Corporation (“Solei”)
and Shahin John Korangy (the “Executive”).

WITNESSETH:

WHEREAS, the Executive
is currently employed as the Company’s Chief Executive Officer and is expected to make major contributions to the short and
long-term profitability, growth and financial strength of the Company; and

WHEREAS, the Company
has determined that appropriate arrangements should be made to encourage the continued attention and dedication of the Executive
to his assigned duties without distraction; and

WHEREAS, in consideration
of the Executive’s employment with the Company, the Company desires to provide the Executive with certain compensation and
benefits as set forth in this Agreement in order to ameliorate the financial and career impact on the Executive in the event the
Executive’s employment with the Company is terminated for a reason related to, or unrelated to, a Change in Control (as defined
below) of the Company.

NOW, THEREFORE,
in consideration of the foregoing and the mutual covenants and agreements hereinafter set forth and intending to be legally bound
hereby, the Company, Solei and the Executive agree as follows:

1. Certain Defined
Terms. In addition to terms defined elsewhere herein, the following terms have the following meanings when used in this Agreement
with initial capital letters:

(a) “Annual
Base Salary” means the Executive’s annual base salary rate, exclusive of bonuses, commissions and other incentive pay,
as set forth in this Agreement and as may be increased from time to time as contemplated herein. Executive’s Annual Base
Salary for the First Year (hereinafter defined) shall be that number of shares of Solei common stock the total fair market value
of which is equal to Two Hundred Fifty Thousand Dollars ($250,000.00) (as determined quarterly on the date of each issuance), in
accordance with Section 2(a) of this Agreement. Executive’s Annual Base Salary for the Second Year (hereinafter defined)
shall be Two Hundred Fifty Thousand Dollars ($250,000.00), which shall be paid in cash in accordance with Section 2(a) of this
Agreement.

(b)       “Board”
means the Board of Directors of Solei.

(c)        “Cause”
means:

(i) an
intentional tort (excluding any tort relating to a motor vehicle) which causes substantial loss, damage or injury to the property
or reputation of the Company, Solei or its affiliates;

 

    	1 

    	 

    

(ii) any proven,
material act of fraud or dishonesty against the Company, Solei or its affiliates;

(iii)
the conviction of a felony that results in material harm to the Company’s business or to the reputation of the Company, Solei
or its affiliates;

(iv) habitual
neglect of Executive’s reasonable duties (for a reason other than illness or incapacity) which is not cured within ten (10) days
after written notice thereof by the Board to the Executive;

(v) the
disregard of written, material policies of the Company or its subsidiaries which causes material loss, damage or injury to the
property or reputation of the Company or its subsidiaries which is not cured within ten (10) days after written notice thereof
by the Board to the Executive; or

(vi) any
material breach of the Executive’s ongoing obligation not to disclose confidential information and not to assign intellectual
property developed during employment which, if capable of being cured, is not cured within ten (10) days after written notice
thereof by the Board to the Executive.

(d)        “Change
in Control” means:

(i) any
person or entity, or group of persons or entities, becoming the beneficial owner, directly or indirectly, of securities of the
Company or Solei representing forty (40%) percent of the total voting power of all its then outstanding voting securities
(other than any person or entity holding 40% or more of such voting power at the Effective Date);

(ii) a
merger or consolidation of the Company or Solei in which its voting securities immediately prior to the merger or consolidation
do not represent, or are not converted into securities that represent, a majority of the voting power of all voting securities
of the surviving entity immediately after the merger or consolidation;

(iii)
a sale of all or substantially all of the assets of the Company or Solei or a liquidation or dissolution of the Company or Solei;
or

(iv) individuals
who, as of the date of the signing of this Agreement, constitute the Board of Directors (the “Incumbent Board”) cease
for any reason to constitute at least a majority of such Board; provided that any individual who becomes a director of the Company
subsequent to the date of the signing of this Agreement, whose election, or nomination for election by the Company stockholders,
was approved by the vote of at least a majority of the directors then in office, shall be deemed a member of the Incumbent Board.

(e)        “COBRA”
means the Consolidated Omnibus Budget Reconciliation Act of 1986, as amended.

 

(f)        “Disability”
means (i) the Executive has been incapacitated by bodily injury, illness or disease so as to be prevented thereby from
engaging in the performance of the Executive’s duties (provided, however, that the Company acknowledges its obligations to
provide reasonable accommodation; (ii) such total incapacity shall have continued for a period of six (6) consecutive
months; and (iii) such incapacity will, in the opinion of a

    	2 

    	 

    

qualified physician, be permanent
and continuous during the remainder of the Executive’s life.

(g)        “Good
Reason Termination” means:

(i) a
material diminution in the Executive’s Annual Base Salary or Target Bonus (hereinafter defined) below the amount as of the
date of this Agreement or as increased during the course of his employment with the Company;

(ii) a
material diminution in the Executive’s authority, duties or responsibilities;

(iii)
a requirement that that the Executive report to any individual or entity other than the Board (or if the Company has a parent corporation,
a requirement that the Executive report to any individual or entity other than the Chief Executive Officer of the ultimate parent
corporation of the Company);

(iv) a
material diminution in the budget over which the Executive retains authority;

(v) a
change in the geographic location at which the Executive must perform services in excess of twenty-five (25) miles; or

(vi) any
action or inaction that constitutes a material breach by the Company or Solei of this Agreement; provided, however, that for the
Executive to be able to terminate his employment with the Company on account of Good Reason he must provide notice of the occurrence
of the event constituting Good Reason and his desire to terminate his employment with the Company on account of such within ninety
(90) days following the initial existence or discovery of the condition constituting Good Reason, and the Company must have
a period of thirty (30) days following receipt of such notice to cure the condition, if curable. If the Company does not cure
the event constituting Good Reason within such thirty (30) day period, the Executive’s Termination Date shall be the
day immediately following the end of such thirty (30) day period, unless the Company provides for an earlier Termination Date.

 

(h)        “Termination
Date” means the last day of Executive’s employment with the Company.

(i)        “Termination
of Employment” means the termination of Executive’s active employment relationship with the Company.

2. Compensation;
Benefits.

 

(a)      
Annual Base Salary. For the period beginning on the Effective Date and ending on the
first anniversary of the Effective Date (the “First Year”), Solei shall pay to Executive, on behalf of the Company,
his Annual Base Salary of shares of Solei common stock in equal installments in accordance with the Company’s standard payroll
practices. For the First Year, the shares of Solei common stock payable to Executive as Annual Base Salary shall be valued as of
the date of payment for each equal installment of Annual Base Salary. For example, if the Company’s standard payroll practice
is to pay payroll every two weeks, each such installment shall equal such number of shares of Solei common stock necessary to cause
Executive to receive shares of Solei common stock equal to $9615.40 per pay period (on a gross basis). Such shares of Solei common
stock shall be valued as of the average trading price of the last 5 days of the quarter.

    	3 

    	 

    

Notwithstanding the foregoing,
any shares of Solei common stock earned by Executive during the First Year shall be issued and delivered to Executive on a quarterly
basis no later than the 25th day of the month following the close of each calendar quarter. Solei shall be permitted
to reduce the number of shares of Solei common stock otherwise deliverable to Executive to cover any income tax withholding and
employee-side payroll tax obligations of Executive, as calculated based on the Executive’s W-4 form filed with the Company
and any equivalent form under applicable state tax laws.

For the period
beginning on the day after the expiration of the First Year and ending on the second anniversary of the Effective Date (the “Second
Year”), the Company shall pay Executive his Annual Base Salary in equal installments in cash in accordance with the Company’s
standard payroll practices. After the expiration of the Initial Term (hereinafter defined), the parties shall meet and confer regarding
the Executive’s Annual Base Salary and shall be reviewed and approved by the compensation committee of the Board of Solei.

Solei shall
guarantee the Company’s payment of Executive’s Annual Base Salary after the expiration of the First Year, in addition
to any severance payments made to Executive hereunder.

(b)        Stock
Award. Within thirty (30) days following the Date of Execution of this Agreement, Solei shall issue to Executive twenty-four
million (24,534,188) shares of the Solei common stock at a price equal to the fair market value as of the Effective Date (“Stock
Award”). The Stock Award shall vest as follows: six million (6,534,188) shares of Solei common stock shall vest as of the
Date of Execution without regard as to Executive’s continued employment with the Company. An additional six million (6,000,000)
shares of Solei common stock shall vest upon the Company’s trailing 12-month gross revenue reaching Fifty Million Dollars
($50,000,000). An additional six million (6,000,000) shares of Solei common stock shall vest upon the Company’s trailing
12-month gross revenue reaching One Hundred Million Dollars ($100,000,000). An additional six million (6,000,000) shares of Solei
common stock shall vest upon the Company’s trailing 12-month gross revenue reaching Two Hundred Million Dollars ($200,000,000).
Notwithstanding the foregoing, any unvested portion of the Stock Award shall vest no later than April 16, 2021, without regard
as to Executive’s continued employment with the Company and without regard to the Company’s achievement of gross revenue
in excess of the above-referenced thresholds. Executive may make an election under Section 83(b) of the Internal Revenue Code of
1986, as amended (the “Code”), and shall, if made, provide Company with a copy of same.

 

(c)       Target
Bonus. In addition to the Annual Base Salary, Executive shall be entitled to

receive a “Target Bonus”
based upon the Company’s trailing 12-month gross revenue reaching Fifteen Million Dollars ($15,000,000) (“Bonus Target
Amount”). The date on which the Company’s trailing 12-month gross revenue reaches the Bonus Target Amount shall be
referred to in this Section 2(c) as the “Bonus Date”. Within 30 days after the Bonus Date, the Company shall issue
to Executive a Target Bonus consisting of: (i) that number of shares of Solei common stock having a fair market value (as of the
Bonus Date) equal to three percent (3%) of the Bonus Target Amount (the “Stock Bonus”); and (ii) cash in an amount
equal to the greater of the following: (1) two percent (2%) of the Bonus Target Amount; or (2) the fair market value of seven and
one-half percent (7.5%) of the Stock Award shares of Solei common stock that vested during the calendar year in which the Bonus
Target Amount was achieved under Section 2(b), valued as of the Bonus

    	4 

    	 

    

Date. The shares issuable under
Section 2(c)(i) shall be issued at the closing market price of Solei common stock as of the close of business on the date which
immediately precedes the Bonus Date and shall vest immediately. Executive’s Target Bonus shall be paid to Executive as soon
as practicable following the close of the calendar year to which such Target Bonus relates, and in no event shall any Target Bonus
be paid after March 15 of the year following the calendar year in which the Target Bonus is earned.

(d) Other Benefits.
Executive shall be entitled to participate in all retirement, life insurance, medical insurance, disability insurance, savings
and other employee benefit programs available to other senior executive level employees of the Company. Additionally, Executive
shall be entitled to ten (10) weeks of paid time off annually.

3.       Termination
Unrelated to a Change in Control.

(a) Involuntary
Termination Unrelated to a Change in Control. In the event of: (i) an involuntary termination of Executive’s employment
by the Company for any reason other than Cause, death or Disability, or (ii) Executive’s resignation for Good Reason,
and if Section 4 does not apply, Executive shall be entitled to the benefits provided in subsection (b) of this Section 3.

(b) Compensation
Upon Termination Unrelated to a Change in Control. Subject to the provisions of Section 6 hereof, in the event a termination
described in subsection (a) of this Section 3 occurs, the Company shall provide Executive with the following, provided
that Executive executes and does not revoke the Release (as defined in Section 6):

(i) 1.5
times the sum of Annual Base Salary and Target Bonus, paid in a single lump sum cash payment on the sixtieth (60th) day
following Executive’s Termination Date. (For purposes of this subsection (i), Annual Base Salary will mean the largest among
the following: Executive’s annual base salary immediately prior to (A) Executive’s Termination Date, or (B) any
reduction of Executive’s base salary described in the first clause of subsection (i) in the definition of Good
Reason. For purposes of this subsection (i), Target Bonus will mean the largest among the following: Executive’s target bonus
immediately prior to (A) Executive’s Termination Date, or (B) any reduction of Executive’s target bonus described
in the first clause of subsection (i) in the definition of Good Reason.)

(ii) For
a period of up to eighteen (18) months following Executive’s Termination Date, Executive and where applicable, Executive’s
spouse and eligible dependents, will continue to be eligible to receive medical coverage under the Company’s medical plans
in accordance with the terms of the applicable plan documents; provided, that in order to receive such continued coverage at such
rates, Executive will be required to pay the applicable premiums to the plan provider, and the Company will reimburse the Executive,
within 60 days following the date such monthly premium payment is due, an amount equal to the monthly COBRA premium payment, less
applicable tax withholdings. Notwithstanding the foregoing, if Executive obtains full-time employment during this eighteen (18) month
period that entitles him and his spouse and eligible dependents to comprehensive medical coverage, Executive must notify the Company
and no further reimbursements will be paid by the Company to the Executive pursuant to this subsection. In addition, if Executive
does not pay the applicable monthly COBRA premium for a particular month at any time during the eighteen (18) month

    	5 

    	 

    

period and coverage is lost
as a result, no further reimbursements will be paid by the Company to the Executive pursuant to this subsection. Notwithstanding
the above, if the Company determines in its sole discretion that it cannot provide the foregoing COBRA benefits without potentially
violating applicable law (including, without limitation, Section 2716 of the Public Health Service Act), the Company shall
in lieu thereof provide to Executive a taxable lump-sum payment in an amount equal to the monthly (or then remaining) COBRA premium
that Executive would be required to pay to continue his group health coverage in effect on the Termination Date (which amount shall
be based on the premium for the first month of COBRA coverage) multiplied by one hundred forty-two percent (142%).

(iii)
With respect to any outstanding Company stock options held by the Executive as of his Termination Date that are not vested and
exercisable as of such date, the Company shall fully accelerate the vesting and exercisability of such stock options, so that all
such stock options shall be fully vested and exercisable as of Executive’s Termination Date, such options (as well as any
outstanding stock options that previously became vested and exercisable) to remain exercisable, notwithstanding anything in any
other agreement governing such options, until the expiration of the original term of the option.

(iv) With
respect to any restricted stock grants or units representing shares of Company common stock (including, without limitation the
Stock Award and any Stock Bonus) (collectively, “Restricted Stock Units”) held by the Executive that are unvested at
the time of his Termination Date, all such unvested Restricted Stock Units shall vest and settle not later than sixty (60) days
following the Termination Date.

(v) Executive
shall receive any amounts earned, accrued or owing but not yet paid to Executive as of his Termination Date, payable in a lump
sum, and any benefits accrued or earned in accordance with the terms of any applicable benefit plans and programs of the Company.

4. Termination
Related to a Change in Control.

(a) Involuntary
Termination Relating to a Change in Control. In the event Executive’s employment is terminated on account of (i) an
involuntary termination by the Company for any reason other than Cause, death or Disability, or (ii) the Executive voluntarily
terminates employment with the Company on account of a resignation for Good Reason, in either case that occurs (x) at the
same time as, or within the twelve (12) month period following, the consummation of a Change in Control or (y) within
the sixty (60) day period prior to the date of a Change in Control where the Change in Control was under consideration at
the time of Executive’s Termination Date, then Executive shall be entitled to the benefits provided in subsection (b) of
this Section 4.

(b) Compensation
Upon Involuntary Termination Relating to a Change in Control. Subject to the provisions of Section 6 hereof, in the event
a termination described in subsection (a) of this Section 4 occurs, the Company shall provide that the following be paid
to the Executive after his Termination Date, provided that Executive executes and does not revoke the Release:

(i) 2.0
times the sum of Annual Base Salary and Target Bonus, paid in a single lump sum cash payment on the sixtieth (60th) day following
Executive’s Termination

    	6 

    	 

    

Date. Notwithstanding the foregoing,
to the extent Executive is entitled to receive the severance benefit payable pursuant to Section 3(b)(i) as a result of a
qualifying termination prior to a Change in Control and then becomes entitled to receive the severance benefit payable pursuant
to this Section 4 as a result of the Change in Control that was considered at the time of Executive’s Termination Date
becoming consummated within sixty (60) days following Executive’s Termination Date, Executive shall not receive the
severance benefit payable pursuant to Section 3(b)(i) of this Agreement, but instead shall receive the severance benefit payable
pursuant to this Section 4(b)(i) on the sixtieth (60th) day following Executive’s Termination Date. (For purposes
of this subsection (i), Annual Base Salary will mean the largest among the following: Executive’s annual base salary immediately
prior to (A) Executive’s Termination Date, (B) any reduction of Executive’s base salary described in the
first clause of subsection (i) in the definition of Good Reason, or (C) immediately prior to the Change in Control.
For purposes of this subsection (i), Target Bonus will mean the largest among the following: Executive’s target bonus (A) immediately
prior to Executive’s Termination Date, (B) immediately prior to any reduction of Executive’s target bonus described
in the first clause of subsection (i) in the definition of Good Reason, (C) immediately prior to the Change in Control,
or (d) for the fiscal year preceding the year in which the Change in Control.)

(ii) For
a period of up to twenty-four (24) months following Executive’s Termination Date, Executive and where applicable, Executive’s
spouse and eligible dependents, will continue to be eligible to receive medical coverage under the Company’s medical plans
in accordance with the terms of the applicable plan documents; provided, that in order to receive such continued coverage at such
rates, Executive will be required to pay the applicable premiums to the plan provider, and the Company will reimburse the Executive,
within sixty (60) days following the date such monthly premium payment is due, an amount equal to the monthly COBRA (or, as
applicable, other) premium payment, less applicable tax withholdings. Notwithstanding the foregoing, if Executive obtains full-time
employment during this twenty-four (24) month period that entitles him and his spouse and eligible dependents to comprehensive
medical coverage, Executive must notify the Company and no further reimbursements will be paid by the Company to the Executive
pursuant to this subsection. In addition, if Executive does not pay the applicable monthly COBRA (or other) premium for a
particular month at any time during the twenty-four (24) month period and coverage is lost as a result, no further reimbursements
will be paid by the Company to the Executive pursuant to this subsection. Notwithstanding the foregoing, to the extent Executive
is entitled to receive the severance benefit provided pursuant to Section 3(b)(ii) of the Agreement as a result of a qualifying
termination prior to a Change in Control, if Executive becomes entitled to receive the severance benefits payable pursuant to this
Section 4 as a result of the Change in Control that was considered at the time of Executive’s Termination Date becoming
consummated within sixty (60) days following Executive’s Termination Date, Executive shall be entitled to receive the
severance benefit provided pursuant to this clause (ii) and not the benefit provided pursuant to Section 3(b)(ii). Notwithstanding
the above, if the Company determines in its sole discretion that it cannot provide the foregoing COBRA benefits without potentially
violating applicable law (including, without limitation, Section 2716

    	7 

    	 

    

of the Public Health Service
Act), the Company shall in lieu thereof provide to Executive a taxable lump-sum payment in an amount equal to the monthly (or then
remaining) COBRA premium that Executive would be required to pay to continue his group health coverage in effect on the Termination
Date (which amount shall be based on the premium for the first month of COBRA coverage) multiplied by one hundred forty-two percent
(142%).

 

(iii) With
respect to any outstanding Company stock options held by the Executive as of his Termination Date that are not vested and exercisable
as of such date, the Company shall fully accelerate the vesting and exercisability of such stock options, so that all such stock
options shall be fully vested and exercisable as of Executive’s Termination Date, such options (as well as any outstanding
stock options that previously became vested and exercisable) to remain exercisable, notwithstanding anything in any other agreement
governing such options until the expiration of the original term of the option.

(iv) With
respect to any Restricted Stock Units held by the Executive that are unvested at the time of his Termination Date, all such unvested
Restricted Stock Units shall vest and settle not later than sixty (60) days following the Termination Date.

(v) Executive
shall receive any amounts earned, accrued or owing but not yet paid to Executive as of his Termination Date, payable in a lump
sum, and any benefits accrued or earned in accordance with the terms of any applicable benefit plans and programs of the Company.

5. Termination
of Employment on Account of Disability, Death, Cause or Voluntarily Without Good Reason.

(a) Termination
on Account of Disability. Notwithstanding anything in this Agreement to the contrary, if Executive’s employment terminates
on account of Disability, Executive shall be entitled to receive disability benefits under any disability program maintained by
the Company that covers Executive, and Executive shall not receive benefits pursuant to Sections 3 and 4 hereof, except that, subject
to the provisions of Section 6 hereof, the Executive shall be entitled to the following benefits provided that Executive executes
and does not revoke the Release:

(i) For
a period of up to eighteen (18) months following Executive’s Termination Date, Executive and where applicable, Executive’s
spouse and eligible dependents, will continue to be eligible to receive medical coverage under the Company’s medical plans
in accordance with the terms of the applicable plan documents; provided, that in order to receive such continued coverage at such
rates, Executive will be required to pay the applicable premiums to the plan provider, and the Company will reimburse the Executive,
within 60 days following the date such monthly premium payment is due, an amount equal to the monthly COBRA premium payment, less
applicable tax withholdings. Notwithstanding the foregoing, if Executive obtains full-time employment during this eighteen (18) month
period that entitles him and his spouse and eligible dependents to comprehensive medical coverage, Executive must notify the Company
and no further reimbursements will be paid by the Company to the Executive pursuant to this subsection. In addition, if Executive
does not pay the applicable monthly COBRA premium for a particular month at any time during the eighteen (18) month

    	8 

    	 

    

period and coverage is lost as
a result, no further reimbursements will be paid by the Company to the Executive pursuant to this subsection. Notwithstanding the
above, if the Company determines in its sole discretion that it cannot provide the foregoing COBRA benefits without potentially
violating applicable law (including, without limitation, Section 2716 of the Public Health Service Act), the Company shall
in lieu thereof provide to Executive a taxable lump-sum payment in an amount equal to the monthly (or then remaining) COBRA premium
that Executive would be required to pay to continue his group health coverage in effect on the Termination Date (which amount shall
be based on the premium for the first month of COBRA coverage) multiplied by one hundred forty-two percent (142%).

(ii) With
respect to any outstanding Company stock options held by the Executive as of his Termination Date that are not vested and exercisable
as of such date, the Company shall fully accelerate the vesting and exercisability of such stock options, so that all such stock
options shall be fully vested and exercisable as of the Executive’s Termination Date, such options (as well as any outstanding
stock options that previously became vested and exercisable) to remain exercisable until the expiration of the original term of
the option.

(iii)
With respect to any Restricted Stock Units held by the Executive that are unvested at the time of his Termination Date, all such
unvested Restricted Stock Units shall vest and settle not later than sixty (60) days following his Termination Date.

(iv) Executive
shall receive any amounts earned, accrued or owing but not yet paid to Executive as of his Termination Date, payable in a lump
sum, and any benefits accrued or earned in accordance with the terms of any applicable benefit plans and programs of the Company.

 

(b) Termination
on Account of Death. Notwithstanding anything in this Agreement to the contrary, if Executive’s employment terminates
on account of death, Executive shall be entitled to receive death benefits under any death benefit program maintained by the Company
that covers Executive, and Executive shall not receive benefits pursuant to Sections 3 and 4 hereof, except that, subject to the
provisions of Section 6 hereof, the Executive shall be entitled to the following benefits, provided that Executive’s
estate executes and does not revoke the Release:

(i) With
respect to any outstanding Company stock options held by the Executive as of his death that are not vested and exercisable as of
such date, the Company shall fully accelerate the vesting and exercisability of such stock options, so that all such stock options
shall be fully vested and exercisable as of the Executive’s death, such options (as well as any outstanding stock options
that previously became vested and exercisable) to remain exercisable until the expiration of the original term of the option.

(ii) With
respect to any Restricted Stock Units held by the Executive that are unvested at the time of his death, all such unvested Restricted
Stock Units shall vest and settle not later than sixty (60) days following his death.

(iii)
Executive’s estate or heirs at law shall receive any amounts earned, accrued or owing but not yet paid to Executive as of
his Termination Date, payable in a lump sum, and any benefits accrued or earned in accordance with the terms of any applicable
benefit plans and programs of the Company.

    	9 

    	 

    

(iv) In
the event the Executive shall die while an employee of the Company, the Company shall have the obligation to purchase and redeem
from the estate of Executive that number of shares of common stock of the Company the value of which (determined as of the date
of Executive’s death) shall equal One Million Five Hundred Thousand and 00/100 Dollars ($1,500,000.00), for a purchase price
equal to One Million Five Hundred Thousand and 00/100 Dollars ($1,500,000.00) (“Purchase Price”). The Company shall
obtain and maintain, at the Company’s expense, an insurance policy on the life of Executive in an amount sufficient to allow
the Company to make the payment of the Purchase Price contemplated by this Section 5(b)(iv). The Purchase Price shall be paid in
a single lump sum via wire transfer or by certified check within sixty (60) days after the date of Executive’s death. Company
shall provide proof of insurance to Executive on an annual basis or upon Executive’s written request.

(c) Termination
on Account of Cause. In the event the Executive’s employment is terminated by the Company on account of Cause, Executive
shall not receive benefits pursuant to Sections 3 and 4 hereof. Notwithstanding the foregoing, Executive shall receive any amounts
earned, accrued or owing but not yet paid to Executive as of his Termination Date, payable in a lump sum, and any benefits accrued
or earned in accordance with the terms of any applicable benefit plans and programs of the Company. In addition, all unvested stock
options or Restricted Stock Units shall continue to vest in accordance with the vesting schedule set forth in Section 2(b) hereof.

(d) Termination
on Account of Voluntary Resignation Without Good Reason. In the event the Executive’s employment is terminated on account
of a resignation by Executive for no reason or any reason other than on account of Good Reason, Executive shall not receive benefits
pursuant to Sections 3 and 4 hereof. Notwithstanding the foregoing, Executive shall receive any amounts earned, accrued or owing
but not yet paid to Executive as of his Termination Date, payable in a lump sum, and any benefits accrued or earned in accordance
with the terms of any applicable benefit plans and programs of the Company. In addition, all unvested stock options or Restricted
Stock Units shall continue to vest in accordance with the vesting schedule set forth in Section 2(b) hereof.

6. Release.
Notwithstanding the foregoing, no payments or other benefits under this Agreement shall be made unless Executive executes, and
does not revoke, the Company’s standard written release, substantially in the form as attached hereto as Exhibit A,
(the “Release”), of any and all claims against the Company and all related parties with respect to all matters arising
out of Executive’s employment by the Company (other than entitlements under the terms of this Agreement or under any other
plans or programs of the Company in which Executive participated and under which Executive has accrued or become entitled to a
benefit) or a termination thereof, with such release being effective not later than sixty (60) days following Executive’s
Termination Date.

7. No Mitigation
Obligation. Executive shall not be required to mitigate the amount of any payment or benefit provided for in this Agreement
by seeking other employment or otherwise, nor shall the amount of any payment or benefit provided for herein be reduced by any
compensation earned by other employment or otherwise.

    	10 

    	 

    

8. Employment
Rights. Nothing expressed or implied in this Agreement will create any right or duty on the part of the Company or the Executive
to have the Executive remain in the employment of the Company or any subsidiary prior to or following any Change in Control.

9. Tax Matters

(a) Withholding
of Taxes. The Company may withhold from any amounts payable under this Agreement all federal, state, city or other taxes as
the Company is required to withhold pursuant to any applicable law, regulation or ruling and Executive shall receive the amount
otherwise payable net of all such withholding taxes due on such payment.

(b) Parachute
Excise Tax. In the event that any amounts payable under this Agreement or otherwise to Executive would (i) constitute
“parachute payments” within the meaning of section 280G of the Code, or any comparable successor provisions and (ii) but
for this Subsection (b) would be subject to the excise tax imposed by section 4999 of the Code or any comparable successor
provisions (the “Excise Tax”), then such amounts payable to Executive hereunder shall be either:

(i) Provided to
Executive in full; or

(ii) Provided to
Executive to the maximum extent that would result in no portion of such benefits being subject to the Excise Tax; whichever of
the foregoing amounts, when taking into account applicable federal, state, local and foreign income and employment taxes, the Excise
Tax and any other applicable taxes, results in the receipt by Executive, on an after-tax basis, of the greatest amount of benefits,
notwithstanding that all or some portion of such benefits may be taxable under the Excise Tax. Unless the Company and Executive
otherwise agree in writing, any determination required under this Subsection (b) shall be made in writing in good faith by
a nationally recognized accounting firm (the “Accountants”). In the event of a reduction in benefits hereunder, the
reduction of the total payments shall apply as follows, unless otherwise agreed in writing and such agreement is in compliance
with section 409A of the Code: (i) any cash severance payments subject to Section 409A of the Code due under this Agreement
shall be reduced, with the last such payment due first forfeited and reduced, and sequentially thereafter working from the next
last payment, (ii) any cash severance payments not subject to Section 409A of the Code due under this Agreement shall
be reduced, with the last such payment due first forfeited and reduced, and sequentially thereafter working from the next last
payment; (iii) any acceleration of vesting of any equity subject to Section 409A of the Code shall remain as originally
scheduled to vest, with the tranche that would vest last (without any such acceleration) first remaining as originally scheduled
to vest; and (iv) any acceleration of vesting of any equity not subject to Section 409A of the Code shall remain as originally
scheduled to vest, with the tranche that would vest last (without any such acceleration) first remaining as originally scheduled
to vest. For purposes of making the calculations required by this Subsection (b), the Accountants may make reasonable assumptions
and approximations concerning applicable taxes and may rely on reasonable, good-faith interpretations concerning the application
of the Code and other applicable legal authority. The Company and Executive shall furnish to the Accountants such information and
documents as the Accountants may reasonably request in order to make a determination under this Subsection (b). The Company shall
bear all costs that the Accountants may reasonably incur in connection with any calculations contemplated by this Subsection (b).

    	11 

    	 

    

If, notwithstanding any reduction described
in this Subsection (b), the Internal Revenue Service (“IRS”) determines that Executive is liable for the Excise Tax
as a result of the receipt of amounts payable under this Agreement or otherwise as described above, then Executive shall be obligated
to pay back to the Company, within thirty (30) days after a final IRS determination or, in the event that Executive challenges
the final IRS determination, a final judicial determination, a portion of such amounts equal to the Repayment Amount. The “Repayment
Amount” with respect to the payment of benefits shall be the smallest such amount, if any, that is required to be paid to
the Company so that Executive’s net after-tax proceeds with respect to any payment of benefits (after taking into account
the payment of the Excise Tax and all other applicable taxes imposed on such payment) are maximized. The Repayment Amount with
respect to the payment of benefits shall be zero if a Repayment Amount of more than zero would not result in Executive’s
net after-tax proceeds with respect to the payment of such benefits being maximized. If the Excise Tax is not eliminated pursuant
to this paragraph, Executive shall pay the Excise Tax.

 

Notwithstanding any other provision of this
Subsection (b), if (i) there is a reduction in the payment of benefits as described in this Subsection (b), (ii) the
IRS later determines that Executive is liable for the Excise Tax, the payment of which would result in the maximization of Executive’s
net after-tax proceeds (calculated as if Executive’s benefits had not previously been reduced), and (iii) Executive
pays the Excise Tax, then the Company shall pay to Executive those benefits which were reduced pursuant to this Subsection (b) as
soon as administratively possible after Executive pays the Excise Tax, so that Executive’s net after-tax proceeds with respect
to the payment of benefits are maximized.

 

10. Term
of Agreement. This Agreement shall continue in full force and effect until the second (2nd) anniversary of the Effective
Date (the “Initial Term”), provided, however, that this Agreement shall remain in effect until all of the obligations
of the parties hereunder are satisfied or have expired.

11. Successors
and Binding Agreement.

(a) The Company
will require any successor (whether direct or indirect, by purchase, merger, consolidation, reorganization or otherwise) to all
or substantially all of the business or assets of the Company, by agreement in form and substance reasonably satisfactory to the
Executive, expressly to assume and agree to perform this Agreement in the same manner and to the same extent the Company would
be required to perform if no such succession had taken place. This Agreement will be binding upon and inure to the benefit of the
Company and any successor to the Company, including without limitation any persons acquiring directly or indirectly all or substantially
all of the business or assets of the Company whether by purchase, merger, consolidation, reorganization or otherwise (and such
successor will thereafter be deemed the “Company” for the purposes of this Agreement), but will not otherwise be assignable,
transferable or delegable by the Company.

(b) This Agreement
will inure to the benefit of and be enforceable by the Executive’s personal or legal representatives, executors, administrators,
successors, heirs, distributees and legatees. This Agreement will supersede the provisions of any employment, severance or other
agreement between the Executive and the Company that relate to any matter that is also the subject of this Agreement, and such
provisions in such other agreements will be null and void.

    	12 

    	 

    

 

(c) This Agreement is
personal in nature and neither of the parties hereto will, without the consent of the other, assign, transfer or delegate this
Agreement or any rights or obligations hereunder except as expressly provided in Sections 10(a) and 10(b). Without limiting the
generality or effect of the foregoing, the Executive’s right to receive payments hereunder will not be assignable, transferable
or delegable, whether by pledge, creation of a security interest, or otherwise, other than by a transfer by the Executive’s
will or by the laws of descent and distribution and, in the event of any attempted assignment or transfer contrary to this Section 10(c),
the Company will have no liability to pay any amount so attempted to be assigned, transferred or delegated.

12. Notices.
For all purposes of this Agreement, all communications, including without limitation notices, consents, requests or approvals,
required or permitted to be given hereunder will be in writing and will be deemed to have been duly given when hand delivered or
dispatched by electronic facsimile transmission (with receipt thereof orally confirmed), or five (5) business days after having
been mailed by United States registered or certified mail, return receipt requested, postage prepaid, or three business days after
having been sent by a nationally recognized overnight courier service such as FedEx or UPS, addressed to the Company (to the attention
of the Secretary of the Company) at its principal executive office and to the Executive at his principal residence, or to such
other address as any party may have furnished to the other in writing and in accordance herewith, except that notices of changes
of address will be effective only upon receipt.

13. Section 409A
of the Code.

(a) Interpretation.
Notwithstanding the other provisions hereof, this Agreement is intended to comply with the requirements of section 409A of the
Code, to the extent applicable, and this Agreement shall be interpreted to avoid any penalty sanctions under section 409A of the
Code. Accordingly, all provisions herein, or incorporated by reference, shall be construed and interpreted to comply with section
409A of the Code and, if necessary, any such provision shall be deemed amended to comply with section 409A of the Code and regulations
thereunder. If any payment or benefit cannot be provided or made at the time specified herein without incurring sanctions under
section 409A of the Code, then such benefit or payment shall be provided in full at the earliest time thereafter when such sanctions
will not be imposed. Any amount payable under this Agreement that constitutes deferred compensation subject to section 409A of
the Code shall be paid at the time provided under this Agreement or such other time as permitted under section 409A of the Code.
No interest will be payable with respect to any amount paid within a time period permitted by, or delayed because of, section 409A
of the Code. All payments to be made upon a termination of employment under this Agreement that are deferred compensation may only
be made upon a “separation from service” under section 409A of the Code. For purposes of section 409A of the Code,
each payment made under this Agreement shall be treated as a separate payment. In no event may Executive, directly or indirectly,
designate the calendar year of payment.

 

(b) Payment Delay.
To the maximum extent permitted under section 409A of the Code, the severance benefits payable under this Agreement are intended
to comply with the “short-term deferral exception” under Treas. Reg. §1.409A-1(b)(4), and any remaining amount
is intended to comply with the “separation pay exception” under Treas. Reg. §1.409A-1(b)(9)(iii); provided, however,
any amount payable to Executive during the six (6) month period following Executive’s Termination Date that does not
qualify within either of the foregoing exceptions and constitutes

    	13 

    	 

    

deferred compensation subject to the requirements
of section 409A of the Code, then such amount shall hereinafter be referred to as the “Excess Amount.” If at the time
of Executive’s separation from service, the Company’s (or any entity required to be aggregated with the Company under
section 409A of the Code) stock is publicly-traded on an established securities market or otherwise and Executive is a “specified
employee” (as defined in section 409A of the Code and determined in the sole discretion of the Company (or any successor
thereto) in accordance with the Company’s (or any successor thereto) “specified employee” determination policy),
then the Company shall postpone the commencement of the payment of the portion of the Excess Amount that is payable within the
six (6) month period following Executive’s Termination Date with the Company (or any successor thereto) for six (6) months
following Executive’s Termination Date with the Company (or any successor thereto). The delayed Excess Amount shall be paid
in a lump sum to Executive within ten (10) days following the date that is six (6) months following Executive’s
Termination Date with the Company (or any successor thereto). If Executive dies during such six (6) month period and prior
to the payment of the portion of the Excess Amount that is required to be delayed on account of section 409A of the Code, such
Excess Amount shall be paid to the personal representative of Executive’s estate within sixty (60) days after Executive’s
death.

(c) Reimbursements.
All reimbursements provided under this Agreement shall be made or provided in accordance with the requirements of section 409A
of the Code, including, where applicable, the requirement that (i) any reimbursement is for expenses incurred during Executive’s
lifetime (or during a shorter period of time specified in this Agreement), (ii) the amount of expenses eligible for reimbursement
during a calendar year may not affect the expenses eligible for reimbursement in any other calendar year, (iii) the reimbursement
of an eligible expense will be made on or before the last day of the taxable year following the year in which the expense is incurred,
and (iv) the right to reimbursement is not subject to liquidation or exchange for another benefit. Any tax gross up payments
to be made hereunder shall be made not later than the end of Executive’s taxable year next following Executive’s taxable
year in which the related taxes are remitted to the taxing authority.

14. Governing
Law; Cost of Enforcement. The validity, interpretation, construction and performance of this Agreement will be governed by
and construed in accordance with the substantive laws of the Commonwealth of Virginia, without giving effect to the principles
of conflict of laws of such State. In the event of any arbitration or litigation arising
under this Agreement or any asserted breach thereof by a party, the substantially prevailing party shall be entitled to recover
all costs and expenses, including reasonable attorneys’ fees, incurred in enforcing or defending any of the terms, covenants
or conditions of this Agreement, including costs incurred prior to commencement of such action and in any appeal.

15. Validity.
If any provision of this Agreement or the application of any provision hereof to any person or circumstances is held invalid, unenforceable
or otherwise illegal, the remainder of this Agreement and the application of such provision to any other person or circumstances
will not be affected, and the provision so held to be invalid, unenforceable or otherwise illegal will be reformed to the extent
(and only to the extent) necessary to make it enforceable, valid or legal.

16. Miscellaneous.
No provision of this Agreement may be modified, waived or discharged unless such waiver, modification or discharge is agreed to
in writing signed by the Executive and the Company. No waiver by either party hereto at any time of any breach by the other party
hereto or compliance with any condition or provision of this Agreement to be performed by such other

    	14 

    	 

    

party will be deemed a waiver of similar
or dissimilar provisions or conditions at the same or at any prior or subsequent time. No agreements or representations, oral or
otherwise, expressed or implied with respect to the subject matter hereof have been made by either party that are not set forth
expressly in this Agreement. References to Sections are to references to Sections of this Agreement. Any reference in this Agreement
to a provision of a statute, rule or regulation will also include any successor provision thereto.

17. Board Membership.
At each annual meeting of the Company’s stockholders prior to the Termination Date, the Company will nominate Executive to
serve as a member of the Board. Executive’s service as a member of the Board will be subject to any required stockholder
approval. Upon the termination of Executive’s employment for any reason, unless otherwise requested by the Board, Executive
agrees to resign from the Board (and all other positions held at the Company and its affiliates), and Executive, at the Board’s
request, will execute any documents necessary to reflect his resignation. In the event the members of the Board are compensated,
Executive shall receive equal compensation, in addition to any other payments due to Executive hereunder.

18. Indemnification
and Insurance. Executive will be provided indemnification to the maximum extent permitted by the Company’s and its subsidiaries’
and affiliates’ Articles of Incorporation or Bylaws. The Company shall obtain and maintain (i) a directors’ and officers’
insurance policy and (ii) an errors and omissions insurance policy, both of which shall insure the Company and the Executive as
of the Effective Date, in amounts that are satisfactory to Executive in his sole discretion.

19. No Duplication
of Benefits. The benefits provided to Executive in this Agreement shall offset substantially similar benefits provided to Executive
pursuant to any other Company policy, plan or agreement.

 

20. Survival. Notwithstanding
any provision of this Agreement to the contrary, the parties’ respective rights and obligations under Sections 3 and 4, will
survive any termination or expiration of this Agreement or the termination of the Executive’s employment for any reason whatsoever.

21. Counterparts.
This Agreement may be executed in one or more counterparts, each of which will be deemed to be an original but all of which together
will constitute one and the same agreement. Electronic or facsimile signatures shall have the same legal effect as originals.

 

 

 

IN WITNESS WHEREOF, the parties have caused
this Agreement to be duly executed and delivered on the dates appearing below.

 

 

 

CARECLIX, INC.

 

	By:_/s/
    Joshua Flood________________________________________
	Name: Joshua Flood

	
        Title: President

        Date: October 10, 2019

 

 

    	15 

    	 

    

	 	 	 
	SOLEI SYSTEMS, INC.
	 	 
	By:
    /s/ Joshua Flood	 	 
	Name: Joshua Flood
	
        Title: President

        Date: October 10, 2019

         

	 
	EXECUTIVE
	 
	_/s/
    Shahin John Korangy___________________________________________
	
        Shahin John Korangy

        October 10, 2019

	 

 

    	16 

    	 

    

 

 

EXHIBIT A

RELEASE OF CLAIMS 

This Release of
Claims (“Agreement”) is made by and between Solei Systems, Inc., a Florida corporation (“Solei”) and Shahin
John Korangy, effective as of ____10-15-19____________ (the “Effective Date”).

WHEREAS, you have
agreed to enter into a release of claims in favor of Solei upon certain events specified in the Executive Employment Agreement
by and between Solei and you;

NOW, THEREFORE,
in consideration of the mutual promises made herein, Solei and you agree as follows:

1. Termination Date. This means the last
day of your employment with Solei.

2. Acknowledgement of Payment of Wages.
You acknowledge that Solei has paid you all accrued wages, salary, bonuses, accrued but unused vacation pay and any similar payment
due and owing, with the exception of the payments and benefits owed to you under the Executive Employment Agreement and/or under
any equity-based compensation awards.

3. Confidential Information. You hereby
acknowledge that you are bound by all confidentiality agreements that you entered into with Solei and/or any and all past and current
parent, subsidiary, related, acquired and affiliated companies, predecessors and successors thereto (which agreements are incorporated
herein by this reference), that as a result of your employment you have had access to the Confidential Information (as defined
in such agreement(s)), that you will hold all such Confidential Information in strictest confidence and that you may not make any
use of such Confidential Information on behalf of any third party. You further confirm that within five business days following
the Termination Date you will deliver to Solei all documents and data of any nature containing or pertaining to such Confidential
Information and that you will not take with you any such documents or data or any reproduction thereof.

4. Release and Waiver of All Claims.
You waive any limitation on this release under Virginia law which provides that a general release does not extend to claims which
a person does not know or suspect to exist in his favor at the time of executing the release which, if known, must have materially
affected his/her decision to grant the release. In consideration of the benefits provided in this Agreement, you release Solei,
and any and all past, current and future parent, subsidiary, related and affiliated companies, predecessors and successors thereto,
as well as their officers, directors, shareholders, agents, employees, affiliates, representatives, attorneys, insurers, successors
and assigns, from any and all claims, liability, damages or causes of action whatsoever, whether known or unknown, which exist
or may in the future exist arising from or relating to events, acts or omissions on or before the Effective Date of this Agreement,
other than those rights which as a matter of law cannot be waived. 

 

You understand and acknowledge that this release
includes, but is not limited to any claim for reinstatement, re-employment, damages, attorney fees, stock options, bonuses or additional
compensation in any form, and any claim, including but not limited to those arising under tort, contract and local, state or federal
statute, including but not limited to Title VII of the Civil Rights

    	17 

    	 

    

Act of 1964, the Civil Rights Act of 1991,
the Post Civil War Civil Rights Act (42 U.S.C. 1981-88), the Equal Pay Act, the Age Discrimination in Employment Act, the Americans
with Disabilities Act, the Vietnam Era Veterans Readjustment Assistance Act, the Fair Labor Standards Act, the Family Medical Leave
Act of 1993, the Uniformed Services Employment and Re-employment Rights Act, the Employee Retirement Income Security Act of 1974,
and the civil rights, employment, and labor laws of any state and any regulation under such authorities relating to your employment
or association with Solei or the termination of that relationship.

You also acknowledge that you are waiving
and releasing any rights you may have under the Age Discrimination in Employment Act (ADEA) and that this waiver and release is
knowing and voluntary. You acknowledge that (1) you have been, and hereby are, advised in writing to consult with an attorney
prior to executing this Agreement; (2) as consideration for executing this Agreement, you have received additional benefits
and compensation of value to which you would otherwise not be entitled, and (3) by signing this Agreement, you will not waive
rights or claims under the Act which may arise after the execution of this Agreement; and (4) you have twenty-one (21) calendar
days within which to consider this Agreement and in the event you sign the Agreement prior to 21 days, you do so voluntarily. Once
you have accepted the terms of this Agreement, you will have an additional seven (7) calendar days in which to revoke such
acceptance. To revoke, you must send a written statement of revocation to the Vice President of Human Resources. If you revoke
within seven (7) days, you will receive no benefits under this Agreement. In the event you do not exercise your right to revoke
this Agreement, the Agreement shall become effective on the date immediately following the seven-day (7) waiting period described
above.

This release does not waive any rights
you may have under any directors and officers insurance or indemnity provision, agreement or policy in effect as of the Termination
Date, nor does it affect vested rights you may have under any equity-based compensation plan, retirement plan, 401(k) plan or other
benefits plan.

5. No Pending or Future Lawsuits. You
represent that you have no lawsuits, claims, or actions pending in your name or on behalf of any other person or entity, against
Solei or any other person or entity referred to herein. You also represent that you do not intend to bring any claims on your own
behalf or on behalf of any other person or entity against Solei or any other person or entity referred to herein.

6. Resignation from Board. You agree
that you will offer your resignation from the Board of Directors effective upon your Termination Date. The Board may accept or
reject your offer of resignation within its sole and absolute discretion.

7. Non-disparagement. The parties hereto
agree that they will not, whether orally or in writing, make any disparaging statements or comments, either as fact or as opinion,
about the other or its/his respective products and services, business, technologies, market position, agents, representatives,
directors, officers, shareholders, attorneys, employees, vendors, affiliates, successors or assigns, or any person acting by, through,
under or in concert with any of them.

 

 

 

    	18 

    	 

    

8. Additional Terms

 

	A.	Legal and Equitable Remedies. You agree that Solei shall have the right to enforce this Agreement and any of its provisions by injunction, specific performance or other equitable relief without prejudice to any other rights or remedies Solei may have at law or in equity for breach of this Agreement. 

 

	B.	Attorney’s Fees. If any action at law or in equity is brought to enforce the terms of this Agreement, the prevailing party shall be entitled to recover from the other party its reasonable attorneys’ fees, costs and expenses at trial or arbitration and any appeal therefrom, in addition to any other relief to which such prevailing party may be entitled. 

 

	C.	Non-Disclosure. You agree to keep the contents, terms and conditions of this Agreement confidential; provided, however that you may disclose this Agreement with your spouse, attorneys, and accountants, or pursuant to subpoena or court order. Any breach of this non-disclosure paragraph is a material breach of this Agreement. 

 

	D.	No Admission of Liability. This Agreement is not, and the parties shall not represent or construe this Agreement, as an admission or evidence of any wrongdoing or liability on the part of Solei, its officers, shareholders, directors, employees, subsidiaries, affiliates, divisions, successors or assigns. Neither party shall attempt to admit this Agreement into evidence for any purpose in any proceeding except in a proceeding to construe or enforce the terms of this Agreement. 

 

	E.	Entire Agreement. This Agreement along with the Executive Employment Agreement, the Intellectual Property and Confidentiality Agreement, and your written equity award agreements with Solei, constitutes the entire agreement between you and Solei with respect to your separation from Solei and supersedes all prior negotiations and agreements, whether written or oral, relating to its subject matter. 

 

	F.	Modification/Successors. This Agreement may not be altered, amended, modified, or otherwise changed in any respect except by another written agreement that specifically refers to this Agreement, and that is duly executed by you and an authorized representative of Solei. This Agreement shall be binding upon your heirs, executors, administrators and other legal representatives and may be assigned and enforced by Solei, its successors and assigns. 

 

	G.	Severability. The provisions of this Agreement are severable. If any provision of this Agreement or its application is held invalid, the invalidity shall not affect other obligations, provisions, or applications of this Agreement that can be given effect without the invalid obligations, provisions, or applications. 

 

	H.	Waiver. The failure of either party to demand strict performance of any provision of this Agreement shall not constitute a waiver of any provision, term, covenant, or condition of this agreement or of the right to demand strict performance in the future. 

 

    	19 

    	 

    

 

	I.	Governing Law and Jurisdiction. This Agreement shall be interpreted and enforced in accordance with the laws of the State of Virginia. The exclusive jurisdiction for any action to interpret or enforce this Agreement shall be the State of Virginia. 

 

	J.	Counterparts. This Agreement may be executed in counterparts, each of which shall be deemed an original, but all of which together shall constitute one and same instrument. 

 

	K.	Voluntary Execution of Agreement. This Agreement is executed voluntarily and without any duress or undue influence on the part of the Parties hereto, with the full intent of releasing all claims. You acknowledge that: 

 

	 	a.	You have read this Agreement; 

 

	 	b.	You understand the terms and consequences of this Agreement and the releases it contains; 

 

	 	c.	You have been advised to consult with an attorney prior to executing this Agreement 

 

	 	d.	You knowingly and voluntarily agree to all the terms in this Agreement and; 

 

	 	e.	You knowingly and voluntarily intend to be bound by this Agreement. 

 

 

	 	 	 	 	 	 	 	 	 
	Sign:	 	 /s/ Shahin
John Korangy

 

	 	 	 	Dated:	 	10-10-19
	 	 	 	 
	Solei Systems, Inc. 	 	 	 	 	 	 
	By		 /s/ Joshua Flood

 

	 	 	 	Dated:	 	10-10-19

 

 

    	20

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00302-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00302-of-00352.parquet"}]]